How to buy Checkpoint Therapeutics stock | $2.68

Checkpoint Therapeutics, Inc is a biotechnology business based in the US. Checkpoint Therapeutics shares (CKPT) are listed on the NASDAQ and all prices are listed in US Dollars. Checkpoint Therapeutics employs 10 staff and has a trailing 12-month revenue of around 0.00.

Checkpoint Therapeutics stock price (NASDAQ: CKPT)

Use our graph to track the performance of CKPT stocks over time.

Checkpoint Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$2.68
52-week range	$1.90 - $5.38
50-day moving average	$2.89
200-day moving average	$3.05
Wall St. target price	$15.80
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.01

Buy Checkpoint Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Checkpoint Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Checkpoint Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Checkpoint Therapeutics price performance over time

Historical closes compared with the close of $2.68 from 2021-05-28

1 week (2021-07-24)	N/A
1 month (2021-07-02)	-11.84%
3 months (2021-05-04)	-2.19%
6 months (2021-01-31)	N/A

1 year (2020-07-31)	N/A
2 years (2019-07-31)	N/A
3 years (2018-07-31)	N/A
5 years (2016-07-31)	N/A

Checkpoint Therapeutics financials

Revenue TTM	$165,000
Gross profit TTM	$-15,283,000
Return on assets TTM	-38.96%
Return on equity TTM	-74.74%
Profit margin	0%
Book value	$0.68
Market capitalisation	$220.1 million

TTM: trailing 12 months

Shorting Checkpoint Therapeutics shares

There are currently 2.4 million Checkpoint Therapeutics shares held short by investors – that's known as Checkpoint Therapeutics's "short interest". This figure is 20.5% up from 2.0 million last month.

There are a few different ways that this level of interest in shorting Checkpoint Therapeutics shares can be evaluated.

Checkpoint Therapeutics's "short interest ratio" (SIR)

Checkpoint Therapeutics's "short interest ratio" (SIR) is the quantity of Checkpoint Therapeutics shares currently shorted divided by the average quantity of Checkpoint Therapeutics shares traded daily (recently around 1.4 million). Checkpoint Therapeutics's SIR currently stands at 1.75. In other words for every 100,000 Checkpoint Therapeutics shares traded daily on the market, roughly 1750 shares are currently held short.

However Checkpoint Therapeutics's short interest can also be evaluated against the total number of Checkpoint Therapeutics shares, or, against the total number of tradable Checkpoint Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Checkpoint Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Checkpoint Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0406% of the tradable shares (for every 100,000 tradable Checkpoint Therapeutics shares, roughly 41 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Checkpoint Therapeutics.

Find out more about how you can short Checkpoint Therapeutics stock.

Checkpoint Therapeutics share dividends

We're not expecting Checkpoint Therapeutics to pay a dividend over the next 12 months.

Checkpoint Therapeutics share price volatility

Over the last 12 months, Checkpoint Therapeutics's shares have ranged in value from as little as $1.9 up to $5.376. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Checkpoint Therapeutics's is 1.6577. This would suggest that Checkpoint Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Checkpoint Therapeutics overview

Checkpoint Therapeutics, Inc. , a clinical-stage immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7. 1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing CK-101, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc.

Frequently asked questions

What percentage of Checkpoint Therapeutics is owned by insiders or institutions?
Currently 16.659% of Checkpoint Therapeutics shares are held by insiders and 22.092% by institutions. How many people work for Checkpoint Therapeutics?
Latest data suggests 10 work at Checkpoint Therapeutics. When does the fiscal year end for Checkpoint Therapeutics?
Checkpoint Therapeutics's fiscal year ends in December. Where is Checkpoint Therapeutics based?
Checkpoint Therapeutics's address is: 2 Gansevoort Street, New York, NY, United States, 10014 What is Checkpoint Therapeutics's ISIN number?
Checkpoint Therapeutics's international securities identification number is: US1628281073 What is Checkpoint Therapeutics's CUSIP number?
Checkpoint Therapeutics's Committee on Uniform Securities Identification Procedures number is: 162828107